[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542028":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":27,"centralContacts":31,"locations":39,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Germans Trias i Pujol Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SSRI treatment",null,"The subjects who will participate in this study will be outpatients seen in the Psychiatry Outpatient Clinics of the Germans Trias i Pujol University Hospital (Badalona, Spain) clinically diagnosed with major depression and eligible to receive antidepressant treatment with SSRIs.\n\nThe control group will be made up of healthy subjects, using the same inclusion and exclusion criteria except for the psychiatric diagnosis.",[13],"Drug: SSRI",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","SSRI","Outpatients with a diagnosis of major depression in the Psychiatry Outpatient Clinics will be evaluated for recruitment.\n\n* Recruitment visit: It will be carried out by one of the psychiatrists participating in the study. The patient will be informed about the study and written consent will be requested. Subsequently, the inclusion and exclusion criteria will be reviewed, and all demographic and clinical variables will be collected.\n* Baseline visit: One of the psychiatrists will interview the patient and apply the semi-structured clinical interview and the psychopathological evaluation questionnaires. In addition, a blood draw will be performed for serum collection, spectral cytometric analysis of lymphocyte subpopulations and obtaining peripheral blood mononuclear cells (PBMCs).\n* Follow-up visit after 3 months of treatment: Clinical variables will be collected and the same procedures will be performed as during the baseline visit. Not in the control group.",[9],[21,22,23,24,25,26],"Sertraline","Citalopram","Escitalopram","Fluoxetine","Paroxetine","Fluvoxamine",[28],{"name":29,"affiliation":5,"role":30},"Maria Iglesias-González, PhD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","+34934651200","maiglesias.germanstrias@gencat.cat",{"name":37,"role":33,"phone":34,"phoneExt":10,"email":38},"Crisanto Díez-Quevedo, PhD","cdiezquevedo.germanstrias@gencat.cat",[40],{"facility":41,"status":10,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":10},"Hospital Universitari Germans Trias i Pujol","Badalona","Catalonia","08916","Spain","ES",{"type":48,"coordinates":49},"Point",[50,51],2.24741,41.45004,{"lat":51,"lon":50},{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100542028","precision-psychiatry-for-depression-immune-response-and-affective-symptoms-as-predictors-of-response-to-antidepressants-100542028",false,"NCT06337539","Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants","LYMPHODEP","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Clinical diagnosis of major depression according to DSM-5 criteria made by a psychiatrist applying the Structured Clinical Interview for DSM-5 (SCID-5).\n* Eligible for receiving antidepressant treatment for major depression.\n\nExclusion Criteria:\n\n* Who have received antidepressant, antipsychotic or euthymizer treatments in the 6 weeks prior to inclusion in the study.\n* Who present concurrent psychotic symptoms.\n* Who present disorders due to alcohol or drug use, with active consumption during the last 3 months.\n* Pregnant women.\n* Who have serious or unstable medical disorders, Addison's or Cushing's disease, systemic inflammatory or autoimmune diseases, or primary or secondary immunodeficiencies.",true,"ALL","18 Years","65 Years",{"count":67,"type":68},50,"ESTIMATED","OBSERVATIONAL","Objectives: To identify in patients with major depression different peripheral markers of neuroinflammation in relation to affective symptoms (anxiety, depression, irritability), fatigue and cognitive symptoms; and its relationship with the response to antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs).\n\nMethodology: This is a prospective observational cohort study in patients with major depression naturally subjected to treatment with SSRIs. For this, 30 patients with major depression attended in the Outpatient Psychiatry Consultations will be selected. All of them will be evaluated at baseline and after 3 months of treatment, collecting demographic and clinical variables, Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) psychiatric diagnoses, psychopathological scales and immunological and biochemical variables. The correlation between immunological markers and affective and cognitive symptoms at baseline, as well as their variation with treatment, will be analyzed. A group of 20 healthy subjects will be used as a control group.\n\nSubsequently, a bivariate comparative analysis will be carried out, where the statistically significant or marginally significant variables associated with psychopathological variables will be used to build a multivariate binary logistic regression model.",[72,73,74,75],"Depression","Inflammation","Antidepressants","Immunity",[77,72,73,75],"Selective serotonin reuptake inhibitors","NOT_YET_RECRUITING","2024-03-22",{"date":81,"type":82},"2024-03-29","ACTUAL",{"date":84,"type":68},"2024-04-01",{"date":86,"type":68},"2027-07-31",{"name":5,"class":6},1]